Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Abstract The authors performed a retrospective and comparative study to compare the efficacy of intravitreal aflibercept and bevacizumab for patients with myopic choroidal neovascularization (mCNV). The patients with treatment-naïve mCNV received 1 + PRN intravitreal bevacizumab from March 2008 to F...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jia-Kang Wang, Tzu-Lun Huang, Pei-Yao Chang, Yen-Ting Chen, Chin-Wei Chang, Fang-Ting Chen, Yung-Ray Hsu, Yun-Ju Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Intravitreal Aflibercept Choroidal Neovascularization Best-corrected Visual Acuity (BCVA) Mean BCVA Aflibercept Group Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b1a16bb2849342a8b7df552ffc71a5b3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1a16bb2849342a8b7df552ffc71a5b3
record_format	dspace
spelling	oai:doaj.org-article:b1a16bb2849342a8b7df552ffc71a5b32021-12-02T11:40:16ZIntravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization10.1038/s41598-018-32761-z2045-2322https://doaj.org/article/b1a16bb2849342a8b7df552ffc71a5b32018-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-32761-zhttps://doaj.org/toc/2045-2322Abstract The authors performed a retrospective and comparative study to compare the efficacy of intravitreal aflibercept and bevacizumab for patients with myopic choroidal neovascularization (mCNV). The patients with treatment-naïve mCNV received 1 + PRN intravitreal bevacizumab from March 2008 to February 2013, while from March 2013 to July 2016 patients were treated by 1 + PRN intravitreal aflibercept, all with monthly follow-up for 12 months. Primary outcome measures included change in central foveal thickness (CFT) in 1 mm by spectral-domain optic coherence tomography, and best corrected visual acuity (BCVA) at month 12. Complications after injections were recorded. The intra-group changes in CFT and BCVA were compared with Wilcoxon signed rank test, the between-group difference compared with Wilcoxon rank sum test. Fisher’s exact test was used for categorical comparison between groups. Seventy-eight eyes of 78 patients were collected. There were 42 eyes in bevacizumab group, with mean age of 53.2 ± 5.4 years and 27 female patients of them. The mean BCVA significantly improved from baseline 0.56 ± 0.35 logMAR to 0.35 ± 0.35 logMAR at Month 12 after bevacizumab treatment (p < 0.001). The mean CFT significantly decreased from baseline 315.3 ± 25.6 μm to 253.7 ± 24.4 μm at Month 12 following intravitreal bevacizumab (p < 0.001). There were 36 eyes in aflibercept group, with mean age of 52.8 ± 6.8 years and 24 female patients of them. The mean BCVA significantly improved from baseline 0.61 ± 0.47 logMAR to 0.38 ± 0.41 logMAR at Month 12 after aflibercept treatment (p < 0.001). The mean CFT significantly decreased from baseline 328.2 ± 19.8 μm to 241.8 ± 27.2 μm at Month 12 following intravitreal aflibercept (p < 0.001). The baseline demographics, lens status, axial length, refractive errors, duration of symptoms, BCVA, and CFT did not differ significantly between groups (p > 0.05). There was no significant difference between bevacizumab and aflibercept groups in BCVA and CFT from Month 1 to Month 12 (p > 0.05). Injection number of aflibercept was 2.11 ± 0.41, less than that of bevacizumab (3.23 ± 0.38) during 12-month period (p = 0.01). There were no systemic thromboembolic event, elevated intraocular pressure, retinal detachment, or infectious endophthalmitis following injections in both groups. We concluded that both aflibercept and bevacizumab can effectively treat choroidal neovascularization in high myopes. Intravitreal aflibercept had similar efficacy but less treatment number than bevacizumab for mCNV during 12-month period.Jia-Kang WangTzu-Lun HuangPei-Yao ChangYen-Ting ChenChin-Wei ChangFang-Ting ChenYung-Ray HsuYun-Ju ChenNature PortfolioarticleIntravitreal AfliberceptChoroidal NeovascularizationBest-corrected Visual Acuity (BCVA)Mean BCVAAflibercept GroupMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-6 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Intravitreal Aflibercept Choroidal Neovascularization Best-corrected Visual Acuity (BCVA) Mean BCVA Aflibercept Group Medicine R Science Q
spellingShingle	Intravitreal Aflibercept Choroidal Neovascularization Best-corrected Visual Acuity (BCVA) Mean BCVA Aflibercept Group Medicine R Science Q Jia-Kang Wang Tzu-Lun Huang Pei-Yao Chang Yen-Ting Chen Chin-Wei Chang Fang-Ting Chen Yung-Ray Hsu Yun-Ju Chen Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
description	Abstract The authors performed a retrospective and comparative study to compare the efficacy of intravitreal aflibercept and bevacizumab for patients with myopic choroidal neovascularization (mCNV). The patients with treatment-naïve mCNV received 1 + PRN intravitreal bevacizumab from March 2008 to February 2013, while from March 2013 to July 2016 patients were treated by 1 + PRN intravitreal aflibercept, all with monthly follow-up for 12 months. Primary outcome measures included change in central foveal thickness (CFT) in 1 mm by spectral-domain optic coherence tomography, and best corrected visual acuity (BCVA) at month 12. Complications after injections were recorded. The intra-group changes in CFT and BCVA were compared with Wilcoxon signed rank test, the between-group difference compared with Wilcoxon rank sum test. Fisher’s exact test was used for categorical comparison between groups. Seventy-eight eyes of 78 patients were collected. There were 42 eyes in bevacizumab group, with mean age of 53.2 ± 5.4 years and 27 female patients of them. The mean BCVA significantly improved from baseline 0.56 ± 0.35 logMAR to 0.35 ± 0.35 logMAR at Month 12 after bevacizumab treatment (p < 0.001). The mean CFT significantly decreased from baseline 315.3 ± 25.6 μm to 253.7 ± 24.4 μm at Month 12 following intravitreal bevacizumab (p < 0.001). There were 36 eyes in aflibercept group, with mean age of 52.8 ± 6.8 years and 24 female patients of them. The mean BCVA significantly improved from baseline 0.61 ± 0.47 logMAR to 0.38 ± 0.41 logMAR at Month 12 after aflibercept treatment (p < 0.001). The mean CFT significantly decreased from baseline 328.2 ± 19.8 μm to 241.8 ± 27.2 μm at Month 12 following intravitreal aflibercept (p < 0.001). The baseline demographics, lens status, axial length, refractive errors, duration of symptoms, BCVA, and CFT did not differ significantly between groups (p > 0.05). There was no significant difference between bevacizumab and aflibercept groups in BCVA and CFT from Month 1 to Month 12 (p > 0.05). Injection number of aflibercept was 2.11 ± 0.41, less than that of bevacizumab (3.23 ± 0.38) during 12-month period (p = 0.01). There were no systemic thromboembolic event, elevated intraocular pressure, retinal detachment, or infectious endophthalmitis following injections in both groups. We concluded that both aflibercept and bevacizumab can effectively treat choroidal neovascularization in high myopes. Intravitreal aflibercept had similar efficacy but less treatment number than bevacizumab for mCNV during 12-month period.
format	article
author	Jia-Kang Wang Tzu-Lun Huang Pei-Yao Chang Yen-Ting Chen Chin-Wei Chang Fang-Ting Chen Yung-Ray Hsu Yun-Ju Chen
author_facet	Jia-Kang Wang Tzu-Lun Huang Pei-Yao Chang Yen-Ting Chen Chin-Wei Chang Fang-Ting Chen Yung-Ray Hsu Yun-Ju Chen
author_sort	Jia-Kang Wang
title	Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
title_short	Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
title_full	Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
title_fullStr	Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
title_full_unstemmed	Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
title_sort	intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/b1a16bb2849342a8b7df552ffc71a5b3
work_keys_str_mv	AT jiakangwang intravitrealafliberceptversusbevacizumabfortreatmentofmyopicchoroidalneovascularization AT tzulunhuang intravitrealafliberceptversusbevacizumabfortreatmentofmyopicchoroidalneovascularization AT peiyaochang intravitrealafliberceptversusbevacizumabfortreatmentofmyopicchoroidalneovascularization AT yentingchen intravitrealafliberceptversusbevacizumabfortreatmentofmyopicchoroidalneovascularization AT chinweichang intravitrealafliberceptversusbevacizumabfortreatmentofmyopicchoroidalneovascularization AT fangtingchen intravitrealafliberceptversusbevacizumabfortreatmentofmyopicchoroidalneovascularization AT yungrayhsu intravitrealafliberceptversusbevacizumabfortreatmentofmyopicchoroidalneovascularization AT yunjuchen intravitrealafliberceptversusbevacizumabfortreatmentofmyopicchoroidalneovascularization
_version_	1718395665414881280

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Ejemplares similares